Education
About Us
Working with TipRanks
Follow Us
TherapeuticsMD (TXMD)
NASDAQ:TXMD
TXMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.70 - $2.44
Previous CloseN/A
Volume92.69K
Average Volume (3M)36.13K
Market Cap
$13.31M
Enterprise Value$13.35M
Total Cash (Recent Filing)$5.75M
Total Debt (Recent Filing)$5.96M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding11,574,362
10 Day Avg. Volume20,973
30 Day Avg. Volume36,131
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.49
Price to Sales (P/S)0.00
P/FCF Ratio8.50
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue2.16
Enterprise Value/Gross Profit7.67
Enterprise Value/Ebitda-1.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
TherapeuticsMD News
PremiumCompany Announcements
TherapeuticsMD Reports Improved Q1 2025 Results
PremiumCompany Announcements
TherapeuticsMD Reports Q1 2025 Financial Results
PremiumCompany Announcements
TherapeuticsMD Reports Improved Financial Performance
PremiumCompany Announcements
TherapeuticsMD Reports Reduced Losses and Revenue GrowthPremiumCompany Announcements
TherapeuticsMD Reports Reduced Losses Amid Strategic ShiftPremiumCompany Announcements
TherapeuticsMD Shifts Focus with Lower Q3 Losses
PremiumCompany Announcements
TherapeuticsMD Releases Preliminary Quarterly Financial ResultsOptions Prices
Currently, No data available
---
Ownership Overview
1.48% Insiders
4.48% Mutual Funds
21.63% Other Institutional Investors
69.20% Public Companies and
Individual Investors
TXMD FAQ
What was TherapeuticsMD’s price range in the past 12 months?
TherapeuticsMD lowest stock price was $0.70 and its highest was $2.44 in the past 12 months.
What is TherapeuticsMD’s market cap?
TherapeuticsMD’s market cap is $13.31M.
When is TherapeuticsMD’s upcoming earnings report date?
TherapeuticsMD’s upcoming earnings report date is Aug 18, 2025 which is in 26 days.
How were TherapeuticsMD’s earnings last quarter?
TherapeuticsMD released its earnings results on May 13, 2025. The company reported -$0.056 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.056.
Is TherapeuticsMD overvalued?
According to Wall Street analysts TherapeuticsMD’s price is currently Overvalued.
Does TherapeuticsMD pay dividends?
TherapeuticsMD does not currently pay dividends.
What is TherapeuticsMD’s EPS estimate?
TherapeuticsMD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TherapeuticsMD have?
TherapeuticsMD has 11,574,362 shares outstanding.
What happened to TherapeuticsMD’s price movement after its last earnings report?
TherapeuticsMD reported an EPS of -$0.056 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.947%.
Which hedge fund is a major shareholder of TherapeuticsMD?
Currently, no hedge funds are holding shares in TXMD
Company Description
TherapeuticsMD
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Technical Analysis
Prophase Labs
―
Aytu BioScience
―
Kala Pharmaceuticals
―
Cosmos Holdings
―
Biofrontera
―